Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after frontline therapy. Advances in chemotherapy, radiation techniques and targeted ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Jozefina Casuscelli discussing the optimal management of de-novo ...

Researchers develop a radiomics-based machine learning model to identify patients with traumatic brain injury at risk ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Chen, M.Y. and Luo, L.P. (2026) CT and MRI Findings of Epithelioid Hemangioma of Bone: A Case Report. Journal of Biosciences and Medicines, 14, 246-252. doi: 10.4236/jbm.2026.143018 .

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...

Charles R. Goulding and Preeti Sulibhavi unpack how AI-driven design and additive manufacturing are changing how surgeons ...

Fusion Dental Implants operates in Roseville, California, providing dental implant services that incorporate modern imaging ...

Background Psoriatic disease has a complex effect on bone metabolism, resulting in both pathological bone formation and bone resorption. However, microstructural changes in cortical and trabecular ...

The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists ...

The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR([1]) . Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand ...

It’s time to bone up on your bone health – a £200 scan is a sound investment to help future-proof your health, says our deputy editor We never used to give our bones a second thought – we can’t see ...